22.63

2.50% -0.58

After Hours: 22.63

Bicycle Therapeutics Plc Adr (BCYC)

Overview News Price History Option Chain Financials Discussions Forecast

Bicycle Therapeutics Plc Adr stock is traded at $22.63, with a volume of 252.81K. It is down -2.50% in the last 24 hours and up +5.26% over the past month. Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Previous Close:

$23.21

Open:

$23.15

24h Volume:

252.81K

Relative Volume:

1.08

Market Cap:

$1.56B

Revenue:

$26.98M

Net Income/Loss:

$-180.66M

P/E Ratio:

-4.8355

EPS:

-4.68

Net Cash Flow:

$-63.56M

1W Performance:

-5.59%

1M Performance:

+5.26%

6M Performance:

-9.12%

1Y Performance:

+12.64%

1-Day Range:

$22.58

$23.55

1-Week Range:

$22.58

$24.66

52-Week Range:

$12.54

$28.20

Bicycle Therapeutics Plc Adr Stock (BCYC) Company Profile

Name

Bicycle Therapeutics Plc Adr

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

011441223261503

Address

BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE

Employee

284

Twitter

@Bicycle_tx

Next Earnings Date

2024-08-19

Latest SEC Filings

BCYC's Discussions on Twitter

Bicycle Therapeutics Plc Adr Stock (BCYC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-11-23	Upgrade	B. Riley Securities	Neutral → Buy
Aug-31-22	Initiated	Cowen	Outperform
Jul-28-22	Initiated	Barclays	Overweight
Jul-06-22	Resumed	Canaccord Genuity	Buy
Apr-13-22	Downgrade	B. Riley Securities	Buy → Neutral
Apr-07-22	Resumed	Cantor Fitzgerald	Overweight
Feb-14-22	Initiated	Morgan Stanley	Equal-Weight
Dec-17-21	Initiated	SVB Leerink	Outperform
Dec-09-21	Initiated	Needham	Buy
Sep-30-21	Initiated	B. Riley Securities	Buy
Apr-20-21	Initiated	JMP Securities	Mkt Outperform
Oct-12-20	Initiated	Cantor Fitzgerald	Overweight
Jun-12-20	Initiated	Oppenheimer	Outperform
Apr-17-20	Initiated	H.C. Wainwright	Buy
Nov-14-19	Initiated	ROTH Capital	Buy
Sep-11-19	Upgrade	Goldman	Neutral → Buy
Jun-17-19	Initiated	Canaccord Genuity	Buy
Jun-17-19	Initiated	Goldman	Neutral
Jun-17-19	Initiated	Jefferies	Buy
Jun-17-19	Initiated	Piper Jaffray	Overweight

View All

Bicycle Therapeutics Plc Adr Stock (BCYC) Latest News

Sep 27, 2024

Wall Street SWOT: Bicycle Therapeutics stock rides high on cancer drug promise - Investing.com

Sep 27, 2024

Sep 20, 2024

A company insider recently sold 246 shares of Bicycle Therapeutics Plc ADR [BCYC]. Should You Sale? - Knox Daily

Sep 20, 2024

Sep 19, 2024

Nothing is Better Than Bicycle Therapeutics Plc ADR (BCYC) stock at the moment - SETE News

Sep 19, 2024

Sep 17, 2024

RBC Capital Mkts initates Bicycle Therapeutics Plc ADR (BCYC) stock to an Outperform - Knox Daily

Sep 17, 2024

Metric Analysis: Bicycle Therapeutics Plc ADR (BCYC)’s Key Ratios in the Limelight - The Dwinnex

Sep 17, 2024

Bicycle Therapeutics Plc ADR: A Year of Highs, Lows, and Market Resilience - The InvestChronicle

Sep 17, 2024

Are Bicycle Therapeutics Plc ADR (BCYC) shares a good deal now? - US Post News

Sep 17, 2024

Hain Celestial Group Inc [HAIN] Investment Guide: What You Need to Know - Knox Daily

Sep 17, 2024

Sep 16, 2024

Bicycle Therapeutics stock maintains Buy rating post-ESMO data By Investing.com - Investing.com UK

Sep 16, 2024

Sep 12, 2024